Wird geladen...
Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
Lefamulin is a novel pleuromutilin antibiotic with potent in vitro activity against key community-acquired bacterial pneumonia (CABP) pathogens. However, the clinical efficacy and safety of lefamulin for treating CABP remains unclear. An integrated analysis of 2 phase III trials investigating the cl...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wolters Kluwer Health
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7373590/ https://ncbi.nlm.nih.gov/pubmed/32702892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000021223 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|